Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | BCEL |
---|---|---|
09:32 ET | 100 | 0.075 |
09:36 ET | 1410 | 0.0852 |
09:56 ET | 200 | 0.09108 |
10:08 ET | 3157 | 0.09135 |
11:13 ET | 100 | 0.0878 |
11:20 ET | 3100 | 0.0914 |
11:44 ET | 1000 | 0.08923 |
11:47 ET | 250 | 0.08868 |
12:03 ET | 100 | 0.0878 |
12:14 ET | 214 | 0.0878 |
12:34 ET | 10000 | 0.08868 |
12:36 ET | 10000 | 0.08885 |
12:38 ET | 10000 | 0.08862 |
12:43 ET | 10000 | 0.08862 |
12:48 ET | 14748 | 0.0877 |
01:30 ET | 8000 | 0.0877 |
01:37 ET | 10000 | 0.0877 |
01:50 ET | 634 | 0.086 |
02:26 ET | 200 | 0.0877 |
02:27 ET | 156 | 0.0864 |
03:27 ET | 2000 | 0.0877 |
03:48 ET | 860 | 0.0884 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Atreca Inc | 3.7M | 0.0x | --- |
Tharimmune Inc | 3.7M | 0.0x | --- |
Clearmind Medicine Inc | 3.6M | 0.0x | --- |
Altamira Therapeutics Ltd | 3.4M | 0.0x | --- |
Bio Path Holdings Inc | 3.4M | -0.1x | --- |
Phio Pharmaceuticals Corp | 4.0M | -0.2x | --- |
Atreca, Inc. is a clinical-stage biopharmaceutical company. The Company is discovering and developing antibody-based therapeutics to treat a range of solid tumor types. Its most advanced product candidate, ATRC-101, is a monoclonal antibody with a mechanism of action and target derived from an antibody identified using its discovery platform. ATRC-101 reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal and breast cancer samples from multiple patients. It commenced clinical development of ATRC-101 with a Phase Ib clinical trial evaluating ATRC-101 as a monotherapy in patients with select solid tumors and opens a new cohort to evaluate ATRC-101 in combination with pembrolizumab, a PD-1 checkpoint inhibitor. It is also advancing additional product candidates using its discovery platform. Its oncology programs include APN-497444, an ADC against a tumor glycan target, and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.7M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 39.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.03 |
EPS | $-2.49 |
Book Value | $2.01 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.